Literature DB >> 10799184

Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome.

G Janetschek1, A Hobisch, R Peschel, A Hittmair, G Bartsch.   

Abstract

PURPOSE: We report the long-term oncological efficacy and morbidity of laparoscopic retroperitoneal lymph node dissection for testicular carcinoma.
MATERIALS AND METHODS: From August 1992 to September 1999, 73 consecutive patients underwent laparoscopic retroperitoneal lymph node dissection with modified unilateral template dissection. All lumbar vessels within the template were routinely transected in the initial 29 cases only. Patients with positive lymph nodes received 2 cycles of chemotherapy.
RESULTS: Operative time ranged from 150 to 630 minutes (mean 221) in our most recent 28 cases. All but 2 operations were completed as planned for a conversion rate of 2.7%. Minor intraoperative complications developed in only 6.8% of cases. In our last 44 patients there was no major and only 1 minor (2.3%) postoperative complication. Mean postoperative hospitalization was 3.3 days. Ejaculation was preserved in all patients. Lymph nodes were positive in 19 cases (26%). Mean followup in 47 patients with pathological stage I disease was 43.3 months (range 7 to 84). We noted 1 retroperitoneal recurrence due to false-negative histological findings but there were no other relapses. At a mean followup of 42.7 months (range 6 to 86) 17 patients with pathological stage II carcinoma treated with 2 cycles of adjuvant chemotherapy were also free of disease.
CONCLUSIONS: In our hands laparoscopic retroperitoneal lymph node dissection has not only proved its surgical efficiency, but also its oncological efficacy. Patient satisfaction is high. During long-term followup of more than 3 years not a single recurrence developed due to surgical failure.

Entities:  

Mesh:

Year:  2000        PMID: 10799184

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Treatment options for clinical stage 1 testis cancer.

Authors:  A I Sagalowsky
Journal:  Proc (Bayl Univ Med Cent)       Date:  2000-10

2.  [Comments on retroperitoneal lymphadenectomy - laparoscopic versus robotic].

Authors:  A Heidenreich
Journal:  Urologe A       Date:  2012-05       Impact factor: 0.639

Review 3.  Critical evaluation of modified templates and current trends in retroperitoneal lymph node dissection.

Authors:  Shane Pearce; Zoe Steinberg; Scott Eggener
Journal:  Curr Urol Rep       Date:  2013-10       Impact factor: 3.092

Review 4.  Frontiers in robot-assisted retroperitoneal oncological surgery.

Authors:  Wesley W Ludwig; Michael A Gorin; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Nat Rev Urol       Date:  2017-09-12       Impact factor: 14.432

Review 5.  Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes.

Authors:  Heather J Chalfin; Wesley Ludwig; Phillip M Pierorazio; Mohamad E Allaf
Journal:  Curr Urol Rep       Date:  2016-05       Impact factor: 3.092

Review 6.  Management of patients with low-stage nonseminomatous germ cell testicular cancer.

Authors:  Andrew J Stephenson; Joel Sheinfeld
Journal:  Curr Treat Options Oncol       Date:  2005-09

Review 7.  [Value of retroperitoneal lymphadenectomy for germ cell cancer].

Authors:  S Krege
Journal:  Urologe A       Date:  2009-01       Impact factor: 0.639

8.  [Multimodal therapy of prostate cancer - 2 case reports].

Authors:  Michael Lamche; Wilhelm A Bauer; Paul Schramek
Journal:  Wien Med Wochenschr       Date:  2008

Review 9.  Laparoscopic retroperitoneal lymph node dissection for nonseminomatous testicular carcinoma.

Authors:  Stefan Corvin; Markus Kuczyk; Aristotelis Anastasiadis; Arnulf Stenzl
Journal:  World J Urol       Date:  2004-03-19       Impact factor: 4.226

10.  Laparoscopic lymph node dissection in urology.

Authors:  Günter Janetschek
Journal:  Curr Urol Rep       Date:  2006-03       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.